The Quercetine Containing Drugs in Pharmacological Correction of Experimental Diabetes with Myocardial Injury
| Autor: | Iryna Stechyshyn, Bohdana Pavliuk |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
obesity medicine.medical_specialty endocrine system diseases Population Specialties of internal medicine hard disease metabolic syndrome 03 medical and health sciences 0302 clinical medicine Diabetes mellitus Internal medicine Diabetic cardiomyopathy Medicine Endothelial dysfunction education education.field_of_study business.industry nutritional and metabolic diseases Type 2 Diabetes Mellitus medicine.disease Obesity 030104 developmental biology RC581-951 030220 oncology & carcinogenesis Etiology Metabolic syndrome antioxydants business |
| Zdroj: | Romanian Journal of Diabetes Nutrition and Metabolic Diseases, Vol 26, Iss 4, Pp 393-399 (2019) |
| ISSN: | 2284-6417 |
| DOI: | 10.2478/rjdnmd-2019-0042 |
| Popis: | Background and aims:The prevalence of diabetes mellitus is becoming an epidemic. The diversity of etiological factors contributes to the fact that both types of diabetes mellitus occur among different age groups and among different segments of the population. Activation of various types of processes that lead to oxidative stress, endothelial dysfunction, the development of atherosclerotic changes, increases the risk of macro- and microvascular complications in diabetes mellitus.Material and methods: The experiments were performed on 172 white Wistar rats weighing 120–150 g. All animals were kept on a standard I. Horbachevsky Ternopil National Medical University (TNMU), vivarium diet. In our studies, for the first time was established a distinct cardioprotective effect of quercetin-containing drugs, Corvitin and Lipoflavon, for the purpose of normalizing disorders in type 1 and type 2 diabetes mellitus coupled with obesity, which opens wide opportunities for the introduction of these drugs into diabetic cardiomyopathy.Results:The results obtained are an experimental rationale for extending the indications of clinical use of Corvitin and Lipoflavon.Conclusion:Lipoflavon in the experimental type 1 and type 2 diabetes mellitus coupled with obesity significantly outperforms Corvitin in terms of TBA-active products and diene conjugates. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|